Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Maintains Outperform on Albemarle, Raises Price Target to $497

Oppenheimer Maintains Outperform on Albemarle, Raises Price Target to $497

Oppenheimer analyst Colin Rusch maintains Albemarle (NYSE:ALB) with a Outperform and raises the price target from $461 to $497.

byBenzinga Newsdesk

January 25, 2023

1 minute read

Oppenheimer analyst Colin Rusch maintains Albemarle (NYSE:ALB) with a Outperform and raises the price target from $461 to $497.

Analyst Ratings

What 5 Analyst Ratings Have To Say About Cormedix

By Benzinga Insights

May 16, 9:02 AM

Within the last quarter, Cormedix (NASDAQ:CRMD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CRMD

Cosmos Holdings Files For Mixed Shelf Offering Of Up To $50M

By Benzinga Newsdesk

September 22, 9:33 AM

- Reuters Citing SEC Filing

COSM

News

Versant Ventures Collaborates With AbCellera To Accelerate Drug Development For Its Portfolio Of Biotech Companies

By Benzinga Newsdesk

July 27, 7:15 AM

AbCellera (NASDAQ:ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant

ABCL

USA NAHB Housing Market Index for Aug 49.000 vs 55.000 Est; Prior 55.000

By Benzinga Newsdesk

August 15, 10:01 AM

USA NAHB Housing Market Index for Aug 49.000 vs 55.000 consensus estimate. The prior reading was 55.000.

SPY

Oppenheimer Maintains Outperform on Albemarle, Raises Price Target to $497

Related Posts

What 5 Analyst Ratings Have To Say About Cormedix

Cosmos Holdings Files For Mixed Shelf Offering Of Up To $50M

Versant Ventures Collaborates With AbCellera To Accelerate Drug Development For Its Portfolio Of Biotech Companies

USA NAHB Housing Market Index for Aug 49.000 vs 55.000 Est; Prior 55.000